All News
Filter News
Found 473 articles
-
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
5/8/2023
23andMe Holding Co., a leading human genetics and biopharmaceutical company, announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.
-
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
4/17/2023
ReCode Therapeutics announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
-
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
4/14/2023
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced results from the Phase 1 portion of its Phase 1/2a study evaluating 23ME-00610, an investigational antibody targeting CD200R1.
-
Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board
4/11/2023
Sonoma Biotherapeutics, Inc. today announced the formation of its scientific advisory board.
-
23andMe Publishes Inaugural Environmental, Social and Governance Report
3/29/2023
23andMe Holding Co. today published its inaugural environmental, social and governance (ESG) report.
-
SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution
3/28/2023
SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.
-
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
3/24/2023
In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.
-
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/14/2023
23andMe Holding Co. announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting being held in Orlando, Florida, April 14-19, 2023.
-
23andMe to Present at Upcoming March 2023 Investor Conferences
2/22/2023
23andMe Holding Co. announced that management will be participating in investor presentations at the following conferences.
-
23andMe Reports FY2023 Third Quarter Financial Results
2/8/2023
23andMe Holding Co. reported its financial results for the third quarter of its fiscal year 2023, which ended December 31, 2022.
-
23andMe to Report FY2023 Third Quarter Financial Results
1/26/2023
23andMe Holding Co. announced that it will report financial results for the fiscal year 2023 third quarter after the market closes on Wednesday, February 8, 2023.
-
Pharmacogenomics (PGx) Market Size - Quantitative Research By QYResearch Medical
11/16/2022
The global Pharmacogenomics (PGx) market is forecasted to grow at a rate of 8.7% from USD 5.66 billion in 2018 to USD 11.01 billion in 2030.
-
DNA Sequencing Market Size 2022 to 2030 - Quantitative Research by QYResearch Medical
11/15/2022
The global DNA sequencing market size was USD 5.30 Billion in 2020 and is expected to register a revenue CAGR of 11.3% during the forecast period.
-
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
11/7/2022
23andMe Holding Co. is presenting a trials-in-progress poster detailing tumor types being evaluated in the expansion phase of its ongoing Phase 1 study for 23ME-00610, an investigational antibody targeting CD200R1 in patients with advanced solid malignancies, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, November 8-12, 2022 in Boston, Massachusetts.
-
23andMe Reports FY2023 Second Quarter Financial Results
11/7/2022
23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the second quarter of its fiscal year 2023, which ended September 30, 2022.
-
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
10/27/2022
23andMe Holding Co. reported that the U.S. Food and Drug Administration granted 510 clearance for its pharmacogenetics report for SLCO1B1 to include interpretive drug information for simvastatin, a common drug used to treat high cholesterol and triglyceride levels.
-
Genomics Market Size, Share Revenue to Grow At 20.9% CAGR Through 2030
10/27/2022
The global Genomics market size was estimated at USD 27.90 billion in 2021 and is expected to surpass around USD 96.25 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 20.9% during the forecast period 2022 to 2030.
-
23andMe to Report FY2023 Second Quarter Financial Results
10/24/2022
23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fiscal year 2023 second quarter after the market closes on Monday, November 7, 2022.
-
GlaxoSmithKline (GSK) announced Tuesday morning it has struck a $70 million deal with Tempus in exchange for expanded access to Tempus’ AI-based patient data platform.
-
23andMe to Present at Upcoming Investor Conferences in November 2022
10/12/2022
23andMe Holding Co. announced that management will be participating in investor presentations at the following conferences: